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Introduction: Treatment free remission (TFR) is a fairly new treatment concept in chronic myeloid leukaemia (CML) that develops 
after two frontier studies from French and Australia published in 2010.  About 40% of CML patients, who have achieved deep 
molecular response (DMR) with tyrosine kinase inhibitor (TKI), are able to remain in TFR after stopping their TKI.  Studies 
are going to search means to increase TFR rate.  Consolidative therapy using interferon (IFN), the standard treatment of CML 
before era of TKI, is a logical possibility because of data suggesting IFN-induced immunity towards the leukemic clone.  We 
conducted the first randomized controlled trial comparing the use of pegIFN versus observation in CML patients attempting TFR. 
Materials & Methods: Adult CML patients from multi-centre in Malaysia with stable DMR for 2 years or more and at least two 
readings of MR4.5, were stopped TKI and randomized into two arms: (1) subcutaneous pegIFN-α-2a starting at 180µg weekly 
for a year, followed by observation, or (2) observation.  Outcome is relapse, defined as either (i) one reading of loss of major 
molecular response (>0.1%IS), or (ii) positivity of BCR-ABL1 transcripts, as confirmed by a second analysis point, indicating 
the increase (≥1 log) in relation to the first analysis point at two successive assessments. Results & Discussion: A total of 30 
patients started intervention from July 2015 to October 2018 (pegIFN n=15, observation n=15).  Analysis was taken on 13th Mar 
2019.  A total of 9 patients relapsed (pegIFN n=4, observation n=5).  The median time of relapse was 13.1 months (range 9.2 to 
25.5) and 1.8 (1.2 to 12.0) after stopping TKI in pegIFN and observation arm, respectively.  Dose of tolerable pegIFN was age 
dependent. Commonest adverse event of pegIFN was transaminitis. Quality of life assessment using EORTC QLO-C30 showed 
similar result between the two arms. Conclusion: PegIFN is a potential consolidative therapy to increase TFR.
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Introduction: Level of BCR-ABL1 fusion gene, the driver mutation in chronic myeloid leukaemia (CML), is monitored using 
quantitative polymerase chain reaction (PCR) (qPCR) reported in International Scale (IS) to guide disease treatment.  BCR-
ABL1 was also found in asymptomatic normal subject without blood/marrow feature of CML.  Previous studies used convenient 
sampling and qualitative PCR or qPCR but not IS to study normal subjects harbouring BCR-ABL1.  Hence, the result could 
neither infer to normal population nor impact treatment of CML.  Materials & Methods: We conducted the first normal population 
study to determine population prevalence of normal subject harbouring BCR-ABL1 using qPCRIS.  It was a cross sectional 
community-based study studying southern Sarawak population aged ≥18 and using two-stage sampling (stratified followed 
by cluster) based on Malaysia Department of Statistics population survey procedure.  The sampling frame was divided into 
enumeration block (EB) and subdivided into living quarter (LQ).  qPCRIS BCR-ABL1 was done using validated commercial kit. 
Results & Discussion: A total of eight EBs, total of 88 LQs and total subject of 190 were studied and analysed.  23 (12.1%) out 
of 190 samples had poor quality with sum of control gene, ABL1, less than 10,000 copy number, while 102 (53.7%) had good 
quality with sum of ABL1 more than 100,00.  Quality of each run of qPCRIS BCR-ABL1 was satisfactory fulfilling the evaluation 
criteria. One subject was found positive, i.e. 0.0023%IS.  Repeat qPCRIS was 0.0032%IS.  Sequencing confirmed e13a2 transcript. 
Conclusions: Prevalence of normal population harbouring BCR-ABL1 in southern Sarawak was 0.5% to 1%. Sum of control 
gene ABL1 copies number in two replicates should be adequate (>100,000) to enable efficient screening.
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Introduction: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder involving the pluripotent haemopoietic 
stem cell compartment. It is caused by a reciprocal translocation between chromosomes 9 and 22, t(9;22) (q34;q11) which 
encodes for the BCR-ABL fusion protein. Discovery of imatinib mesylate (IM) as targeted BCR-ABL protein kinase inhibitor 
